The energy giant's 2018 LNG outlook report contains plenty of insights for investors.
The industrial biotech pioneer announced full-year 2017 earnings.
You can make a strong argument for buying either pipeline stock, but there are key differences to consider.
North American energy independence and booming exports mean energy product companies are ready to roll -- but some are better positioned than others.
Management expects a big year of growth in 2018.
The troubled utility (and its customers) will get a bailout from Dominion Energy if the merger goes through. How will it affect shareholders?
Electricity is still the company's bread and butter, but its foray into natural gas is proving valuable.
The genetic testing leader was subpoenaed by a major regulatory agency.
The technology giant doesn't manufacture lithium-ion batteries, but that may not stop it from securing a future supply of cobalt for its devices.
The industrial giant is quietly well-positioned to dominate next-generation biotechnology -- and not just in healthcare.
The gene-editing pioneer announced full-year 2017 results and issued a business update.
The small cap biotech company provided disappointing guidance for 2018.
When it comes to cryptocurrencies and blockchains, there's a lot of talk about smart contracts. But what are they, exactly?
The biopharma released full-year 2017 earnings yesterday after the market closed.
The largest food company in the United States has made important comments on its most recent conference call and at an industry talk.
NiSource isn't a household name among investors, but the low-risk utility stock -- and its 3.4% dividend -- deserves a little more attention.
The biopharma announced full-year 2017 results and provided a business update for its late-stage pipeline.
The biopharma announced full-year 2017 results and several business updates.
The fertilizer stock has stumbled out of the starting blocks in 2018, but momentum could be building.
The biopharma's slide continues -- for good reason this time.